SHENZHEN, China, Nov. 25, 2015 /PRNewswire/ -- China Nepstar Chain Drugstore Ltd. (NYSE: NPD) ("Nepstar" or the "Company"), a leading retail drugstore chain in China based on the number of directly operated stores, today announced its unaudited financial results for the third quarter ended September 30, 2015.
Financial Highlights
For the quarter ended September 30, 2015:
-- Same store sales increased by 13.2% compared to the third quarter of 2014 -- Revenue increased by 7.4% to RMB793.0 million (US$124.8 million) compared to the third quarter of 2014 -- Gross margin was 40.9% -- Opened 47 stores while closed 30 stores in the third quarter of 2015, with 1,965 stores as of September 30, 2015 -- Net loss was RMB2.8 million (US$0.4 million)
Ms. Rebecca Zhang, Chief Executive Officer of Nepstar, commented, "Our dedicated efforts on growing store productivity propelled the increase in revenue and same store sales. We continued to optimize the marketing programs and product mix to drive the improvement in gross margin. We will further optimize our management structure to achieve the organizational efficiency from head office to stores."
Third Quarter Results
During the third quarter of 2015, the Company opened 47 new stores while it closed 30 stores. As of September 30, 2015, the Company had 1,965 directly operated stores in total.
Revenue for the third quarter of 2015 increased by 7.4% to RMB793.0 million (US$124.8 million) from RMB738.3 million for the same period in 2014. Same store sales (for the 1,740 stores opened before December 31, 2013 and which were still operating as of September 30, 2015) for the third quarter of 2015 increased by 13.2% compared to the same period in 2014. The increase in same store sales was primarily due to in-store marketing initiatives and improved product mix.
Third quarter revenue contribution by product category was 23.4% from prescription drugs (22.7% for the same period in 2014), 43.1% from over-the-counter ("OTC") drugs (38.7% for the same period in 2014), 17.6% from convenience and other products (21.0% for the same period in 2014), 11.5% from nutritional supplements (13.6% for the same period in 2014), and 4.4% from herbal products (4.0% for the same period in 2014).
Third quarter gross profit was RMB324.0 million (US$51.0 million) compared to RMB298.3 million in the same period of 2014. Gross margin in the third quarter of 2015 was 40.9%, compared with 40.4% in the same period of 2014. The year-over-year increase in gross margin was mainly the result of improved product mix and increased store productivity.
The Company's portfolio of private label products expanded to 2,165 types of products as of September 30, 2015. Sales of private label products represented approximately 13.6% of the Company's revenue and 20.5% of the gross profit for the third quarter of 2015.
Sales, marketing and other operating expenses as a percentage of revenue decreased slightly to 37.0% for the third quarter of 2015 from 37.9% in the same period of 2014.
General and administrative expenses as a percentage of revenue were 3.3% for the third quarter of 2015 compared to 4.1% for the same period of 2014. This was mainly due to the Company's efforts to improve efficiencies and the write-off of certain accounts payables when the de-recognition threshold was met.
Income from operations in the third quarter of 2015 was RMB4.5 million (US$0.7 million) compared with loss from operations of RMB13.1 million in the same period of 2014. This increase was mainly due to the continuous revenue growth and improved margin.
Interest and investment income for the third quarter of 2015 was RMB1.1 million (US$0.2 million), compared with RMB1.5 million in the same period of 2014.
The Company's income tax expense was RMB8.4 million. The difference in the effective income tax rate and the PRC statutory tax rate of 25% applicable to our major operating subsidiaries was primarily due to non-deductible expenses and the operating losses from certain loss-making subsidiaries, for which full valuation allowances were made on their deferred tax assets, when compared to the overall results of operation of the Company. Shareholders are reminded that in the PRC, losses in companies which are part of a group are not allowed to be off-set against profits arising from other companies in the same group.
Net loss for the third quarter of 2015 was RMB2.8 million (US$0.4 million), or RMB0.03 (US$0.004) per basic and diluted ADS compared to net loss of RMB 13.1 million, or RMB0.13 basic and diluted losses per ADS for the third quarter of 2014. As of September 30, 2015, the Company had 197.4 million outstanding ordinary shares. Each ADS represents two ordinary shares of the Company.
In the third quarter of 2015, net cash inflow from operating activities were RMB27.4 million (US$4.3 million), compared to net cash outflow of RMB1.2 million for the same period in 2014.
As of September 30, 2015, the Company's total cash, cash equivalents, short-term and long-term bank deposits and restricted cash were RMB346.0 million (US$54.4 million) and its shareholders' equity was RMB834.1 million (US$131.2 million), compared with total cash, cash equivalents, bank deposits and restricted cash of RMB316.9 million and shareholders' equity of RMB831.6 million as of December 31, 2014.
Business Outlook
"Product mix and store staff will be our two key focuses next. We will strive to improve store image to increase the loyalty with our customers. While keeping the goal of maintaining gross margin, we will continue to optimize product mix and omni-channel marketing campaigns. We are confident that, with continued improvements in performance of each store, we will maintain our growth momentum," Ms. Zhang concluded.
Conference Call Information
The Company will host a conference call, to be simultaneously webcasted, on Wednesday, November 25, 2015 at 8:00 a.m. Eastern Standard Time / 9:00 p.m. Beijing Time. Interested parties may participate in the conference call by dialing +1-877-407-9210 (North America) or +1-201-689-8049 (International) approximately five minutes before the call start time. A live web cast of the conference call will be available on the Nepstar website at www.nepstar.cn.
A replay of the call will be available shortly after the conclusion of the conference call through December 1, 2015 at 11:59 p.m. Eastern Standard Time. An archived web cast of the conference call will be available on the Nepstar website at http://www.nepstar.cn. Interested parties may access the replay by dialing +1-877-660-6853 (North America) or +1-201-612-7415 (International) and entering conference ID number 13623845.
About China Nepstar Chain Drugstore Ltd.
China Nepstar Chain Drugstore Ltd. (NYSE: NPD) is a leading retail drugstore chain in China. As of September 30, 2015, the Company had 1,965 directly operated stores across 71 cities, one headquarter distribution center and 14 regional distribution centers in China. Nepstar uses directly operated stores, centralized procurement and a network of distribution centers to provide its customers with high-quality, professional and convenient pharmaceutical products and services and a wide variety of other merchandise, including OTC drugs, nutritional supplements, herbal products, personal care products, family care products, and convenience products. Nepstar's strategy of centralized procurement, competitive pricing, customer loyalty programs and private label offerings has enabled it to capitalize on the continuing economic growth in China and take advantage of the demographic trend in China to achieve a strong brand and leading market position. For further information, please go to http://www.nepstar.cn.
Safe Harbor Statement
This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the quotations from management in this press release and the Company's strategic operational plans and business outlook, contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.
Exchange Rate Information
The United States dollar (US$) amounts disclosed in this press release are presented solely for the convenience of the reader. Translations of amounts from RMB into United States dollars were calculated at the certified exchange rate of US$1.00 = RMB6.3556 on September 30, 2015 as set forth in the H.10 weekly statistical release of the Federal Reserve Board. No representation is made that the RMB amounts could have been, or could be, converted into US$ at that rate on September 30, 2015, or at any other date. The percentages stated are calculated based on RMB amounts.
Contacts
Zixin Shao
China Nepstar Chain Drugstore Ltd.
Chief Financial Officer
+86-755-2641-4065
ir@nepstar.cn
(Tables Follow)
China Nepstar Chain Drugstore Ltd. Unaudited Condensed Consolidated Statements of Comprehensive Loss (amounts in thousands -- except per-share and per-ADS data) Three-month period ended September 30, 2014 2015 2015 RMB RMB USD Revenue 738,334 792,995 124,771 Cost of goods sold (440,022) (468,986) (73,791) -------- -------- ------- Gross profit 298,312 324,009 50,980 Sales, marketing and other operating expenses (279,496) (293,077) (46,113) General and administrative expenses (30,173) (26,462) (4,164) Impairment losses of property and equipment (1,740) - - (Loss)/income from operations (13,097) 4,470 703 Interest and investment income 1,487 1,096 173 Other income 2,956 117 18 (Loss)/income before income tax expense (8,654) 5,683 894 Income tax expense (4,467) (8,439) (1,328) Net loss (13,121) (2,756) (434) ======= ====== ==== Basic and diluted loss per ordinary share (0.066) (0.014) (0.002) Basic and diluted loss per ADS (0.132) (0.028) (0.004) Net loss (13,121) (2,756) (434) Other comprehensive loss, net of tax: Foreign currency translation adjustments (10) (52) (8) Comprehensive loss (13,131) (2,808) (442) ======= ====== ====
China Nepstar Chain Drugstore Ltd. Unaudited Condensed Consolidated Balance Sheets (amounts in thousands) As of As of As of December 31, September 30, September 30, 2014 2015 2015 RMB RMB USD ASSETS Current assets Cash and cash equivalents 252,174 336,849 53,000 Short-term bank time deposits 24,000 9,000 1,416 Long-term bank time deposits due within one year 3,256 - - Restricted cash 37,423 124 20 Accounts receivable, net of allowance for doubtful 136,568 145,080 22,827 accounts Bills receivable 400 - - Amounts due from related parties 3,366 4,216 663 Prepaid expenses, deposits and other current assets 245,254 165,448 26,032 Inventories 546,312 593,959 93,454 Deferred tax assets 2,038 4,885 769 ----- ----- --- Total current assets 1,250,791 1,259,561 198,181 --------- --------- ------- Non-current assets Property and equipment, net 137,750 166,415 26,184 Rental deposits 42,257 43,884 6,905 Cost method investments 12,638 12,493 1,966 Intangible assets, net 2,509 2,509 395 Goodwill 51,819 51,819 8,153 Deferred tax assets 16,340 11,372 1,789 Other non-current assets - 37,443 5,891 --- ------ ----- Total non-current assets 263,313 325,935 51,283 ------- ------- ------ Total assets 1,514,104 1,585,496 249,464 ========= ========= ======= LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities Accounts payable 409,428 476,941 75,043 Amounts due to related parties 25,636 22,811 3,589 Accrued expenses and other payables 122,236 122,400 19,258 Income tax payable 25,743 23,860 3,754 Deferred income 25,715 37,395 5,884 ------ ------ ----- Total current liabilities 608,758 683,407 107,528 ------- ------- ------- Non-current liabilities Deferred income 15,677 12,908 2,031 Deferred tax liabilities 14,711 15,091 2,374 Other non-current liabilities 43,326 39,949 6,286 ------ ------ ----- Total non-current liabilities 73,714 67,948 10,691 ------ ------ ------ Total liabilities 682,472 751,355 118,219 ------- ------- ------- Shareholders' equity Share capital 158 158 25 Additional paid-in capital 640,341 640,341 100,752 Accumulated other comprehensive loss (41,746) (41,805) (6,578) Retained earnings 232,879 235,447 37,046 ------- ------- ------ Total shareholders' equity 831,632 834,141 131,245 ------- ------- ------- Total liabilities and shareholders' equity 1,514,104 1,585,496 249,464 ========= ========= =======
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/china-nepstar-chain-drugstore-ltd-reports-third-quarter-2015-financial-results-300184406.html
SOURCE China Nepstar Chain Drugstore Ltd.